BGPartner advises OrbiMed, Novo Holdings and Catalio Capital on $181.4 mio Series D financing of Alentis Therapeutics AG
12. November 2024
Swiss biotech company Alentis Therapeutics AG successfully closed a $181.4 mio oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors.
The funding round was led by OrbiMed with co-leads Novo Holdings and Jeito Capital. New investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capitalparticipated in the round. Significant backing was also received from existing investor RA Capital Management, along with support from Morningside Venture Investments, BB Pureos, Bpifrance through its InnoBio 2 fund.
The financing will support Alentis Therapeutics AG to develop a deep pipeline of CLDN1 targeted medicines for solid tumors.
BGPartner advised lead investors OrbiMed and Novo Holdings as well as the investor Catalio Capital on all Swiss legal matters and the negotiations of this Series D financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate).
More information about our legal and negotiation expertise can be found here.